{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=21",
    "query": {
      "intervention": "Control Study Product",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 4228,
    "total_pages": 423,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T06:35:14.760Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02218489",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blepharitis"
      ],
      "interventions": [
        {
          "name": "KPI-121",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kala Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2014-07",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2021-01-11",
      "last_synced_at": "2026-10-21T06:35:14.760Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02218489"
    },
    {
      "nct_id": "NCT06852768",
      "title": "Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "oGHVD"
      ],
      "interventions": [
        {
          "name": "d-MAPPS",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PI and Patient Masked",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Regenerative Ocular Immunobiologics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2025-01-10",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-21T06:35:14.760Z",
      "location_count": 6,
      "location_summary": "Beverly Hills, California • Huntington Beach, California • Palm Harbor, Florida + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Palm Harbor",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06852768"
    },
    {
      "nct_id": "NCT05198323",
      "title": "A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "LT3001 Drug Product",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lumosa Therapeutics Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 66,
      "start_date": "2022-08-11",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-21T06:35:14.760Z",
      "location_count": 1,
      "location_summary": "Chattanooga, Tennessee",
      "locations": [
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05198323"
    },
    {
      "nct_id": "NCT05737485",
      "title": "Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Ciliary Dyskinesia"
      ],
      "interventions": [
        {
          "name": "RCT1100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ReCode Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2023-02-18",
      "completion_date": "2025-01-13",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-21T06:35:14.760Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05737485"
    },
    {
      "nct_id": "NCT02188160",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndromes",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "KPI-121",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kala Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2014-06",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-10-21T06:35:14.760Z",
      "location_count": 11,
      "location_summary": "Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02188160"
    },
    {
      "nct_id": "NCT06305780",
      "title": "RECOVER-AUTONOMIC Platform Protocol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID",
        "Long Covid19",
        "Long Covid-19"
      ],
      "interventions": [
        {
          "name": "IVIG + Coordinated Care",
          "type": "DRUG"
        },
        {
          "name": "IVIG Placebo + Coordinated Care",
          "type": "DRUG"
        },
        {
          "name": "Ivabradine + Coordinated Care",
          "type": "DRUG"
        },
        {
          "name": "Ivabradine Placebo + Coordinated Care",
          "type": "DRUG"
        },
        {
          "name": "IVIG + Usual Care",
          "type": "DRUG"
        },
        {
          "name": "IVIG Placebo + Usual Care",
          "type": "DRUG"
        },
        {
          "name": "Ivabradine + Usual Care",
          "type": "DRUG"
        },
        {
          "name": "Ivabradine Placebo + Usual Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kanecia Obie Zimmerman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 381,
      "start_date": "2024-03-11",
      "completion_date": "2025-07-09",
      "has_results": true,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-21T06:35:14.760Z",
      "location_count": 50,
      "location_summary": "Opelika, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more",
      "locations": [
        {
          "city": "Opelika",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305780"
    },
    {
      "nct_id": "NCT04854096",
      "title": "Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "NS-018",
          "type": "DRUG"
        },
        {
          "name": "Best Available Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NS Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2023-01-31",
      "completion_date": "2024-05-16",
      "has_results": true,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-10-21T06:35:14.760Z",
      "location_count": 3,
      "location_summary": "Worcester, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04854096"
    },
    {
      "nct_id": "NCT01493596",
      "title": "A Safety, Tolerability and Pharmacokinetic Study of CPP-115",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Dependency"
      ],
      "interventions": [
        {
          "name": "CPP-115",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Catalyst Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 55,
      "start_date": "2011-12",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2021-04-20",
      "last_synced_at": "2026-10-21T06:35:14.760Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01493596"
    },
    {
      "nct_id": "NCT07398508",
      "title": "NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Menkes Disease"
      ],
      "interventions": [
        {
          "name": "Droxidopa Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Placebo Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stephen G. Kaler",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 6,
      "start_date": "2026-08-10",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-21T06:35:14.760Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07398508"
    },
    {
      "nct_id": "NCT03768440",
      "title": "Continuous Erector Spinae Block Versus Continuous Paravertebral Block",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "continuous erector spinae block (ESB)",
          "type": "PROCEDURE"
        },
        {
          "name": "continuous paravertebral block (PVB)",
          "type": "PROCEDURE"
        },
        {
          "name": "Ropivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "1 Month to 12 Years"
      },
      "enrollment_count": 34,
      "start_date": "2019-04-16",
      "completion_date": "2025-02-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-10-21T06:35:14.760Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03768440"
    }
  ]
}